This webinar discusses the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.
Interleukin-2 (IL-2) is a component of most protocols of ACT, but it is limited by short exposure and high toxicities. NKTR-214 is a kinetically engineered IL-2 receptor βγ-biased agonist designed to preferentially activate and expand effector T and natural killer cells over regulatory T cells in the tumor.
In this webinar, Giulia Parisi of the University of California, Los Angeles, discusses the use of in vivo immuno-imaging to track the biodistribution of the adoptively transferred T cells in relation to anti-tumor efficacy. She will also discuss how this study used single-cell proteomics and functional biomarkers to characterize the functional phenotype of the cell subsets modulated by ACT+NKTR-214.
The objectives of this seminar are to:
- Provide an overview of the use of an engineered IL-2 receptor agonist in adoptive cell transfer protocols
- Present methods to track T cell anti-tumor activity and in vivo biodistribution
- Describe the application of single-cell functional proteomics in identifying biomarkers in next-generation therapies